Related Experiment Video

Updated: Jun 6, 2025

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

6.9K

Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine-Glycine-Aspartate)

Bojana Bogdanović1, Daniel Fagret1, Catherine Ghezzi1

  • 1INSERM, CHU Grenoble Alpes, Laboratory of Bioclinical Radiopharmaceutics, University Grenoble Alpes, 38000 Grenoble, France.

Pharmaceuticals (Basel, Switzerland)
|November 27, 2024
PubMed

Insights

Integrin-targeted therapies show promise for cancer diagnosis and treatment. New RGD-based strategies and dual-targeting approaches aim to overcome limitations and improve efficacy for better patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Integrins are key cell adhesion receptors crucial for cancer progression, metastasis, and angiogenesis.
  • Integrin-targeted therapies hold significant diagnostic and therapeutic potential but face clinical challenges like variable efficacy.
  • Limitations of traditional RGD-based agents include inconsistent target expression and rapid clearance, hindering effectiveness.

Purpose of the Study:

  • To review recent advancements in RGD-integrin research.
  • To address limitations of previous integrin-targeted therapies.
  • To explore novel dual-targeting strategies and RGD-based agents for improved cancer diagnosis and therapy.

Main Methods:

  • Comprehensive literature review of RGD-integrin field advancements.
  • Analysis of new dual-targeting approaches.
  • Evaluation of cutting-edge RGD-based agents for diagnostic and therapeutic applications.

Main Results:

  • Identified limitations in traditional RGD-based agents.
  • Highlighted advancements in RGD-based strategies.
  • Introduced novel dual-targeting approaches and agents for enhanced specificity and efficacy.

Conclusions:

  • New RGD-based strategies and dual-targeting approaches offer improved solutions for integrin-targeted cancer therapy.
  • These advancements pave the way for more effective cancer diagnosis and treatment.
  • Further research in this area promises enhanced specificity and efficacy in clinical applications.
Keywords:
PET imagingRGD-binding integrindual targetingsolid tumorstheranosticαvβ3

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.0K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
3.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Selectins01:25

Selectins

Cell adhesion is  an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
3.3K